ストックスクリーナーアプリを入手
0.80
23.08%
0.15
プレマーケット:
.78
-0.02
-2.50%
前日終値:
$0.65
開ける：
$0.66
24時間の取引高:
440.29K
Relative Volume:
0.51
時価総額：
$809.02K
収益：
-
当期純損益:
$-19.39M
株価収益率:
-0.0423
EPS:
-18.9115
ネットキャッシュフロー:
$-15.34M
1週間 パフォーマンス:
-23.08%
1か月 パフォーマンス:
-48.39%
6か月 パフォーマンス:
-87.46%
1年 パフォーマンス:
+255.56%
1日の値動き範囲:
$0.62
$0.80
1週間の範囲:
$0.619
$1.67
52週間の値動き範囲:
$0.0927
$15.90
Glucotrack Inc Stock (GCTK) Company Profile
Compare GCTK vs ISRG, BDX, ALC, MDLN, RMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
GCTK
Glucotrack Inc
|
0.80 | 809.02K | 0 | -19.39M | -15.34M | -18.91 |
ISRG
Intuitive Surgical Inc
|
464.45 | 164.96B | 10.06B | 2.88B | 2.49B | 7.876 |
BDX
Becton Dickinson Co
|
156.34 | 44.47B | 21.92B | 1.76B | 2.63B | 6.1223 |
ALC
Alcon Inc
|
75.51 | 36.81B | 10.40B | 980.00M | 1.61B | 1.9749 |
MDLN
Medline Inc
|
44.00 | 35.71B | 28.43B | 1.16B | 1.26B | 1.4457 |
RMD
Resmed Inc
|
222.85 | 32.46B | 5.40B | 1.49B | 1.78B | 10.12 |
Glucotrack Inc (GCTK) 最新ニュース
Glucotrack reports net loss of USD 19.4M in FY 2025 - Medical Buyer
Glucotrack, Inc. 2025 Annual Report – Implantable Continuous Blood Glucose Monitor Development, Regulatory Progress, and Risk Factors 66 - Minichart
GCTK: Improved net loss and cash position support 2026 clinical trial launch for implantable CBGM - TradingView
Glucotrack (GCTK) advances implantable CBGM but flags going concern risk - Stock Titan
GlucoTrack, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - MarketScreener
Glucotrack (NASDAQ: GCTK) trims 2025 loss and readies IDE for implantable CBGM trials - Stock Titan
Glucotrack, Inc. Announces IDE Filing Plans for Continuous Blood Glucose Monitoring Technology and Patents Issued by USPTO - Quiver Quantitative
Glucotrack’s 3-year glucose implant targets a U.S. human trial in 2026 - Stock Titan
GCTK stock is soaring pre-market today — what is fueling the surge? - MSN
Technical Analysis: What analysts say about GlucoTrack Inc stock2026 Analyst Calls & Low Drawdown Trading Techniques - baoquankhu1.vn
GlucoTrack Plummets 27%: Is This the Bottom of a Deep Downtrend? A High-Stakes Analysis for 2026 - Bitget
GCTK PE Ratio & Valuation, Is GCTK Overvalued - Intellectia AI
GlucoTrack Prepares FDA Submission for Implantable CBGM Trial - The Globe and Mail
Glucotrack plans FDA submission for implantable glucose monitor By Investing.com - Investing.com Australia
Glucotrack to File for FDA Exemption Based on 2025 Milestones - Yahoo Finance
GCTK Stock Is Soaring Today — What Is Fueling The Surge? - Stocktwits
Glucotrack to Submit IDE Application to FDA in Early Q2 - citybiz
Glucotrack, Inc. (GCTK) Stock: Prepares FDA Submission as Clinical Data Shows Strong Accuracy - parameter.io
Glucotrack plans US trial of implantable glucose monitor this year - MedTech Dive
Microcap MedTech Moving on U.S. Clinical Milestone - The Globe and Mail
GCTK stock GlucoTrack NASDAQ +29.80% on FDA IDE plan 27 Mar 2026: Earnings in focus - meyka.com
Latest Developments Propel GCTK Stock with Breakthrough Acquisitions - StocksToTrade
Why Is GlucoTrack Stock Soaring Friday?GlucoTrack (NASDAQ:GCTK) - Benzinga
GlucoTrack (GCTK) Surges 45% in Afternoon Trading—What's Fueling This Unusual Move? - Bitget
Glucotrack Inc Files Significant Ide with Fda for Us Clinical Trial in Early Second Quarter Based on Critical 2025 Milestones - marketscreener.com
Glucotrack plans FDA submission for implantable glucose monitor - Investing.com
Glucotrack to file IDE with FDA in Q2 2026 after successful human trials and new patents - TradingView
GCTK Stock Is Soaring Pre-Market Today — What Is Fueling The Surge? - Stocktwits
Glucotrack (NASDAQ: GCTK) advances implantable CBGM with IDE plan and new patents - Stock Titan
Glucotrack to file significant IDE with FDA for US clinical trial in early Q2 based on critical 2025 milestones - MarketScreener
Glucotrack Plans IDE Submission to FDA in Early Q2 2026 for Non-Invasive Glucose Monitoring Clinical Trials - geneonline.com
Glucotrack to File Significant IDE with FDA for US Clinical Trial in Early Q2 Based on Critical 2025 Milestones - marketscreener.com
Brazil and Australia trials put Glucotrack on path to a U.S. diabetes study - Stock Titan
GlucoTrack Stock Gains As Data Backs FDA Filing Plans For Glucose Monitoring Tech - Sahm
Is GlucoTrack Inc. a stock for growth or value investorsWeekly Market Outlook & Weekly Top Stock Performers List - baoquankhu1.vn
Sentiment Review: What analysts say about GlucoTrack Inc stockOptions Play & Precise Entry and Exit Recommendations - baoquankhu1.vn
Growth Recap: Is GlucoTrack Inc backed by strong institutional buying2026 Closing Moves & Short-Term High Return Ideas - baoquankhu1.vn
GlucoTrack Shareholders Approve Capital Flexibility and Auditor Ratification - The Globe and Mail
GlucoTrack, Inc. 8-K SEC Filing: Company Details, Nasdaq Listing, and Key Disclosures (March 2026) - Minichart
Glucotrack shareholders approve stock issuances and auditor ratification - Investing.com
Glucotrack (GCTK) investors approve large stock and warrant issuances - Stock Titan
GCTK SEC FilingsGlucotrack 10-K, 10-Q, 8-K Forms - Stock Titan
Glucotrack to Present at LSI USA ’26 Medtech Innovation Summit - Yahoo Finance
Chart Watch: Will GlucoTrack Inc benefit from geopolitical trendsMarket Movement Recap & Safe Capital Growth Plans - baoquankhu1.vn
GCTK Earnings History & Surprises | EPS & Revenue Results | GLUCOTRACK INC (NASDAQ:GCTK) - ChartMill
GCTK Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
GCTK Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Risk Recap: Should value investors consider GlucoTrack IncJuly 2025 Momentum & Daily Technical Stock Forecast Reports - baoquankhu1.vn
Exit Recap: Can Oaktree Acquisition Corp III Life Sciences Equity Warrant benefit from deglobalization2025 Stock Rankings & Daily Growth Stock Investment Tips - baoquankhu1.vn
Armistice (GCTK) reports 9.99% stake — 101,075 shares disclosed - Stock Titan
Is GlucoTrack Inc. stock a buy before product launchesM&A Rumor & Technical Confirmation Alerts - mfd.ru
Glucotrack Inc (GCTK) 財務データ
収益
当期純利益
現金流量
EPS
1.45%
0.76%
大文字化:
|
ボリューム (24 時間):